Science Overview

Pursuing Novel Oncology Targets

Sierra is building a broad and diverse pipeline of promising oncology assets against emerging targets at the leading edge of cancer biology. Our two assets, SRA737 and SRA141 target the DNA Damage Response (DDR) network, a scientifically validated approach with far-reaching potential across oncology.